Shutoku Matsuyama

Publication Activity (10 Years)

Years Active: 2020-2022
Publications (10 Years): 4

Top Topics

Replacement Therapy

Respiratory Syndrome Coronavirus

Placebo Controlled

Top Venues

Journal of virology

This page only lists publications with an associated author ORCID identifier.

Publications

Akihiro Doi, Yuriko Tomita, Hiyori Okura, Shutoku Matsuyama
Frequent occurrence of mutations in nsp3 and nsp4 of SARS-CoV-2, presumably caused by the inhaled asthma drug ciclesonide. PNAS nexus 1 (4) (2022)
Akihiro Doi, Yuriko Tomita, Hiyori Okura, Shutoku Matsuyama
Frequent occurrence of mutations in nsp3 and nsp4 of SARS-CoV-2, presumably caused by the inhaled asthma drug ciclesonide. PNAS nexus 1 (4) (2022)
Yuriko Tomita, Shutoku Matsuyama, Hideo Fukuhara, Katsumi Maenaka, Hiroaki Kataoka, Takao Hashiguchi, Makoto Takeda
The Physiological TMPRSS2 Inhibitor HAI-2 Alleviates SARS-CoV-2 Infection. Journal of virology 95 (12) (2021)
Shutoku Matsuyama, Miyuki Kawase, Naganori Nao, Kazuya Shirato, Makoto Ujike, Wataru Kamitani, Masayuki Shimojima, Shuetsu Fukushi
The Inhaled Steroid Ciclesonide Blocks SARS-CoV-2 RNA Replication by Targeting the Viral Replication-Transcription Complex in Cultured Cells. Journal of virology 95 (1) (2020)